Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

4.26
+1.7066.41%
Post-market: 4.340.0801+1.88%19:59 EST
Volume:80.20M
Turnover:382.33M
Market Cap:316.68M
PE:-2.94
High:6.16
Open:2.59
Low:2.56
Close:2.56
52wk High:6.16
52wk Low:1.60
Shares:74.34M
Float Shares:58.98M
Volume Ratio:106.91
T/O Rate:135.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4506
EPS(LYR):-1.2306
ROE:-37.26%
ROA:-17.24%
PB:1.31
PE(LYR):-3.46

Loading ...

Perspective Therapeutics (CATX) Gets a Buy from Wedbush

TIPRANKS
·
Jan 13

Perspective Therapeutics Price Target Maintained With a $14.00/Share by BTIG

Dow Jones
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Myriad Genetics (MYGN)

TIPRANKS
·
Jan 13

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities

TIPRANKS
·
Jan 12

Perspective Therapeutics Announces Plans to Advance Clinical Pipeline, Expand Manufacturing Capacity, and Present Updated Data at 2026 Medical Conferences

Reuters
·
Jan 12

Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Reuters
·
Jan 12

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

TIPRANKS
·
Jan 09

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Jan 09

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
Jan 09

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04, 2025

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28, 2025

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26, 2025

Perspective Therapeutics Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Nov 24, 2025

Perspective Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Nov 22, 2025

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics price target lowered to $7 from $18 at UBS

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire
·
Nov 20, 2025

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Nov 19, 2025

B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating

MT Newswires Live
·
Nov 18, 2025

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17, 2025